MA stargazing reveals a different story
All the Medicare Advantage trend lines seem like they are northward bound. Enrollment, the number of plans, the number of companies selling those plans — they’re all up. So Avalere Health’s report last month on the percentage of beneficiaries in highly rated plans stood out — and not in a good way.
All the Medicare Advantage trend lines seem like they are northward bound. Enrollment, the number of plans, the number of companies selling those plans — they’re all up. So Avalere Health’s report last month on the percentage of beneficiaries in highly rated plans stood out — and not in a good way.
Related: Medicare Advantage Enrollment Keeps Growing
CMS’ Star Rating program grades the quality of Medicare Advantage plans on a scale of 1 to 5 stars, with 5 being the highest quality.
Using data that the CMS made available in October, Avalere Health calculated that approximately 11.9% of the enrollees in Medicare Advantage plans that include drug coverage are in 5-star plans, which isn’t a big difference from the 11% of enrollees in 5-star plans last year.
But the consulting firm’s numbers show that the proportion of enrollees in 4.5-star plans dropped sharply, from 31.4% last year to 19.6% this year, and the proportion in 4-star plans dipped from 38.8% last year to 30.9% this year.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
CVS Caremark Makes Changes in Diabetes Coverage for 2025
Published: November 25th 2024 | Updated: November 25th 2024CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More
